VLRX - Valeritas Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2950
+0.0079 (+2.75%)
As of 2:49PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2871
Open0.2900
Bid0.2931 x 1800
Ask0.2959 x 3000
Day's Range0.2860 - 0.2961
52 Week Range0.2810 - 2.0800
Volume480,962
Avg. Volume1,454,577
Market Cap30.351M
Beta (3Y Monthly)11.08
PE Ratio (TTM)N/A
EPS (TTM)-1.7110
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Valeritas to Report First Quarter 2019 Financial Results on May 9, 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it will release financial results for the first quarter of 2019 after the close of trading on Thursday, May 9, 2019. Valeritas’ management team will host a corresponding conference call beginning at 4:30 p.m. ET. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • GlobeNewswire15 days ago

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment

    BRIDGEWATER, N.J., April 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced.

  • GlobeNewswire22 days ago

    Valeritas partners with the American Association of Diabetes Educators (AADE)

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for people with diabetes, today announced it is proudly partnering with the AADE on their Diabetes Advanced Network Access (DANA) technology resource website, DANAtech.org. DANA was launched in 2018 by the AADE as a source for healthcare professionals to keep up with technology options for people with diabetes, prediabetes and other cardio metabolic conditions.

  • GlobeNewswire26 days ago

    Valeritas Announces V-Go® Distribution Agreement in Israel

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it signed an exclusive distribution agreement with TRITECH BioMed for the commercialization of its V-Go® Wearable Insulin Delivery device in Israel. Under the terms of the agreement, TRITECH BioMed will have the rights to promote, market and sell the V-Go to diabetes clinics and patients in Israel.

  • GlobeNewswirelast month

    Valeritas to Present at the Oppenheimer 29th Annual Healthcare Conference

    BRIDGEWATER, N.J., March 12, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of VLRX earnings conference call or presentation 5-Mar-19 9:30pm GMT

    Q4 2018 Valeritas Holdings Inc Earnings Call

  • GlobeNewswire2 months ago

    Valeritas Reports Fourth Quarter and Full Year 2018 Financial Results

    BRIDGEWATER, N.J., March 05, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • ACCESSWIRE2 months ago

    Valeritas Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 5, 2019 / Valeritas Holdings, Inc. (NASDAQ: VLRX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 5, 2019 at 4:30 ...

  • GlobeNewswire2 months ago

    Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that the Compensation Committee of Valeritas’ Board of Directors granted stock options to purchase an aggregate of 244,400 shares of Valeritas’ common stock to 31 newly-hired employees, with a grant date of February 27, 2019, pursuant to the Valeritas Holdings, Inc. 2018 Inducement Plan that was previously disclosed.  The stock options were granted as inducements material to the new employees entering into employment with Valeritas in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $0.479 per share, the closing price of Valeritas’ common stock on February 27, 2019.

  • ACCESSWIRE2 months ago

    Healthcare Stocks Leading the Sector

    HENDERSON, NV / ACCESSWIRE / February 22, 2019 / Below are several healthcare companies in the news leading the sector recently. A company in the sector that has not had news recently but according to ...

  • ACCESSWIRE2 months ago

    Tech Stocks to Watch Today

    CORAL GABLES, FL / ACCESSWIRE / February 21, 2019 / The recent success of the healthcare stock market can be attributed to the fact that companies in the healthcare industry are looking into new innovative approaches and technologies to better improve their offerings for consumers. Whereas cannabis was previously condemned as a harmful substance, medical experts have released studies showing that medicinal cannabis can be used to reduce inflammation caused by inflammatory diseases, as well as help patients suffering from acute anxiety, and countless other uses. In addition to the medical field shifting towards accepting medicinal cannabis, the healthcare sector, overall, has placed more emphasis on investing in the patient and their quality of life.

  • GlobeNewswire2 months ago

    Switching to Valeritas’ V-Go® Wearable Insulin Delivery Device from Insulin Pen Devices for Basal-Bolus Therapy Improved Glycemic Control with Less Insulin

    BRIDGEWATER, N.J., Feb. 21, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire2 months ago

    Valeritas to Present at Upcoming Investor Conferences

    BRIDGEWATER, N.J., Feb. 19, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire2 months ago

    Valeritas to Report Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced it will release financial results for the fourth quarter and full year 2018 after the close of trading on Tuesday, March 5, 2019.  The company’s management team will host a corresponding conference call beginning at 4:30 PM EST. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks Setting The Pace On Monday (1/14/19)

    CORAL GABLES, FL / ACCESSWIRE / January 14, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Microbot Medical Inc (MBOT), Valeritas Holdings Inc (VLRX), and Opko Health Inc (OPK) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • GlobeNewswire3 months ago

    Valeritas Announces V-Go® Received Preferred Status on OptumRx Formularies

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that V-Go is Preferred on the OptumRx formulary. “We are very excited that V-Go is now Preferred on OptumRx formularies,” said Valeritas CEO, John Timberlake. “V-Go helps patients simplify their insulin therapy and improve their management of diabetes.

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Gaining Speed on Thursday (1/3/19)

    CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the ...

  • GlobeNewswire4 months ago

    Valeritas Announces V-Go® is Preferred on Humana Part D Formularies

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch for patients with diabetes, today announced that Humana, one of the nation’s leading health and well-being companies in the United States, has given V-Go Preferred status on Humana’s Part D formularies. “We are very excited that V-Go is now Preferred on Humana’s Medicare formularies, which will improve patient access to V-Go at an affordable monthly copay for its members with type 2 diabetes,” said Valeritas CEO, John Timberlake.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of VLRX earnings conference call or presentation 9-Nov-18 1:30pm GMT

    Q3 2018 Valeritas Holdings Inc Earnings Call

  • 5 Beaten-Down Medical Product Stocks to Rebound in 2019
    Zacks4 months ago

    5 Beaten-Down Medical Product Stocks to Rebound in 2019

    As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.

  • GlobeNewswire5 months ago

    Valeritas CEO John Timberlake to Participate as a Panelist on “Exploring Innovation in Diabetes Tech,” at DeviceTalks West Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that John Timberlake, CEO, will be a panelist at DeviceTalks West, a MassDevice resource, being held December 11-12, 2018, at the Hilton Orange County/Costa Mesa in Costa Mesa, California. Mr. Timberlake will participate in a panel titled, “Exploring Innovation in Diabetes Tech," scheduled on Wednesday, December 12, 2018, from 11:00-11:45 AM Pacific Time. Mr. Timberlake, along with representatives from other diabetes device companies, will discuss current and future technologies for patients with diabetes.

  • GlobeNewswire5 months ago

    Study Supports Valeritas’ V-Go® Can Improve Glycemic Control in Type 2 Patients When Using an Easy to Follow Physician-Driven Insulin Titration Algorithm

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the publication of a manuscript titled “Evaluation of a Weekly Physician-Driven Bolus Titration Algorithm in Patients with Type 2 Diabetes Prescribed V-Go® Wearable Insulin Delivery Device for Basal-Bolus Therapy,” in a special Bolus Insulin issue of Annals of Diabetes, Metabolic Disorders & Control, an international, peer-reviewed journal.

  • GlobeNewswire5 months ago

    Valeritas Announces Pricing of $36 Million Public Offering

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the pricing of its underwritten public offering of (i) 75 million shares of its common stock, (ii) series A warrants to purchase 75 million shares of its common stock and (iii) series B warrants to purchase 75 million shares of its common stock, for gross proceeds of $36 million, at a public offering price of $0.48 per share and accompanying warrants. The series A warrants have an exercise price of $0.60 per share, are immediately exercisable and will expire on the fifth anniversary of the date of issuance.